First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Michael Schenker, Bogdan Żurawski, J. Menezes(Hospital Nossa Senhora da Conceição), Eduardo Richardet(Instituto Oncológico de Córdoba), Jaafar Bennouna(Inserm), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Óscar Juan(Hospital Universitari i Politècnic La Fe), Aurelia Alexandru(Institutul Oncologic Bucuresti), Hiroshi Sakai(Saitama Cancer Center), Alejo Lingua(Instituto Médico Río Cuarto), Pamela Salman(Fundación Arturo López Pérez), Pierre-Jean Souquet(Hôpital Lyon Sud), Pedro De Marchi(Hospital de Câncer de Barretos), Claudio Martín(Instituto Alexander Fleming), M. Pérol(Centre de Recherche en Cancérologie de Lyon), Arnaud Scherpereel(Inserm), Shun Lü(Shanghai Chest Hospital), Thomas John(Austin Hospital), David P. Carbone(The Ohio State University), S. Meadows–Shropshire(Bristol-Myers Squibb (United States)), Shruti Agrawal(Bristol-Myers Squibb (United States)), Abderrahim Oukessou(Bristol-Myers Squibb (United States)), Jinchun Yan(Bristol-Myers Squibb (United States)), Martin Reck(German Center for Lung Research)
Cited by 1,351
Abstract
Related Papers
No related papers found
Powered by citation graph analysis